Abstract: Acute bacterial meningitis causes a substantial number of deaths in Cameroon. Among 170 children with acute meningitis, 112 were positive for a bacterial pathogen when tested using polymerase chain reaction amplification, and Streptococcus pneumoniae accounted for 57.1% of cases. and Neisseiria meningitidis are major pathogens responsible for invasive diseases in children beyond the neonatal period. Sub-Saharan Africa has one of the greatest burden of disease attributable to these bacteria, accounting for an estimated 500,000 deaths per year in the region in 2000.
quotient score in 14 of 18 (78%) infants in whom SNHL was excluded during the second year of life was 102.9 (SD 7.9), and the mean score of the language subscale was 15.7 months (SD 1.5). Both scores were not different compared with scores of infants in whom hearing tests were not performed. Viral load in 17 of 18 (94%) infants in whom hearing was tested during the second year of life did not differ from viral load in 64 of 66 (97%) infants who were not tested at that time (median: 3.3 × 10 5 copies/mL versus 3.1 × 10 5 copies/mL, P = 0.8).
DISCUSSION
This study shows that preterm infants with postnatally acquired CMV infection do not develop SNHL during the first 2 years of life.
CMV is an important cause of SNHL in children. In contrast to congenitally infected infants, little is known about hearing in preterm infants with postnatal CMV infection. Audiologic followup of infants with postnatal CMV infection has so far only been studied twice and has been limited to small numbers of patients. [4] [5] [6] In the first study, 30 postnatally infected preterm infants with GA between 35 and 37 weeks were tested at 3 years of age, and all had normal hearing. 4 In the second study, 22 infected preterm infants born before 32 weeks of gestation were evaluated at 2 and 4.5 years of age, respectively. 5 None of the infected infants developed SNHL. Furthermore, in 20 of these previously studied infants the hearing was tested again at school age, and none of them developed SNHL. 6 This is in line with our study where we found no SNHL in 64 infected preterm infants during the first year of life and in 18 during the second year of life regardless of the presence of cerebral abnormalities, clinical symptoms of CMV disease or urine CMV load. Moreover, the neurodevelopmental scores using the GMDS including language subscale were normal in all infants with and without hearing test at 18 months of corrected age. As the language subscale of the GMDS score may not exclude mild sensorineural hearing deficit (such as auditory neuropathy), the hearing of infected infants will be assessed again at school age.
Recently, the relationship between postnatal CMV infection and development of SNHL (including auditory neuropathy) in a preterm infant was suggested. 10 This infant, born at a GA of 26 weeks developed CMV infection within 3 weeks of age, and at term-equivalent age bilateral auditory neuropathy was diagnosed. At 4 years of age, her language perception was normal and her language expression was mildly delayed. The suggestion that extremely low birth weight infants who develop CMV infection within several weeks after birth are at high risk of developing auditory deficit cannot be confirmed in our study. None of the 21 (25%) infants born ≤27 weeks of gestation and none of the 5 of 6 symptomatic infants in whom hearing was tested (median GA: 27.3 weeks, range: 26.0-29.6) developed SNHL during the first year of life. In the second year of life, hearing of 8 infants born ≤27 weeks of gestation and 2 symptomatic infants was tested; none of them had SNHL.
It is of interest that the development of lenticulostriate vasculopathy, which was documented in 35% of studied infants, was not associated with hearing loss. The exact mechanism of acquiring SNHL caused by CMV infection is still unknown; however, it may be the result of persistent cochlear inflammation.
11 CMV has been recently isolated from the inner ear of a 15-month-old boy 1 month after a documented primary CMV infection. 12 A limitation of our study is the limited number (18/84, 21%) of preterm infants with CMV infection that could be tested during the second year of life. All parents of nontested infants were convinced that their children had no hearing deficits and therefore they refused a hearing test between 18 and 24 months of age. It is, however, likely that severe hearing impairment among infants who were not tested during the second year of life would have been recognized using GMDS and its language subscale. Furthermore, there were no differences in viral load and other hearing loss risk factors between tested and nontested infants. Because progressive SNHL caused by CMV infection may sporadically develop in later life, future evaluation of hearing in our population is still desirable. Neurodevelopmental outcome of infected and noninfected infants will be assessed in the near future. In conclusion, postnatally acquired CMV infection among preterm infants is not related with SNHL during the first and second year of life.Accepted for publication May 09, 2012. 
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S treptococcus pneumoniae, Haemophilus influenzae type b (Hib)
and Neisseiria meningitidis are major pathogens responsible for invasive diseases in children beyond the neonatal period. Sub-Saharan Africa has one of the greatest burden of disease attributable to these bacteria, accounting for an estimated 500,000 deaths per year in the region in 2000. 1 The case fatality rate for pneumococcal meningitis can be as high as 50%.
2 Therefore, the introduction of conjugate vaccines against these bacteria has been recommended by the World Health Organization, but has been constrained by competing public health priorities, and by limited information on the disease burden and bacterial serogroup/serotype distribution associated with these infections in most African countries. If Hib is responsible for more than 90% of all invasive diseases due to this bacterial species, the issue of the potential vaccine coverage is more difficult to assess for S. pneumoniae because more than 90 serotypes have been described, and pneumococcal serotypes have different geographical distributions. 3 Although most of the 7 serotypes included in the 7-valent pneumococcal conjugate vaccine are common worldwide, additional serotypes are frequently encountered in developing countries and must be included into vaccines to maximize their effect in these countries. 4 Serotypes 1 and 5, for example, cause a much greater proportion of disease in developing countries than they do in developed countries. 5, 6 Serotypes 3, 7F and 19A are also important serotypes of global disease burden. 7 In Africa, serotype determination and surveillance have been performed in a limited number of countries and extrapolated for the rest of the continent. Johnson et al 8 published a systematic studybased review of serotypes causing invasive pneumococcal disease across the 5 continents but data of only 13 of 53 African countries were available, most of them coming from eastern Africa. Ideally, a surveillance program should be implemented in each country to allow the health authorities to better define their public health priorities based on vaccine cost-effectiveness studies. 9 In Cameroon, limited data are available on the respective role of S. pneumoniae, Hib and N. meningitidis in invasive diseases and none on circulating pneumococcal serotypes. As a Global Alliance for Vaccines and Immunization-eligible country, Cameroon introduced Hib conjugate vaccine and a 13-valent pneumococcal conjugate vaccine (PCV-13, Prevenar13, Pfizer Inc., New York, NY) in 2010 and 2011, respectively, in the absence of good epidemiologic data on local disease. The aims of our study were to assess the etiology of bacterial meningitis in Cameroonian children and to determine pneumococcal serotypes before PCV introduction.
METHODS
A prospective multicenter observational study was conducted from January 2008 to December 2009 in 3 distant locations with different climatic conditions in Cameroon: The Mother and Child Hospital of Chantal Biya Foundation at Yaounde in the central province (damp plain), the district hospital of Dschang in the western province (mountain) and the district hospital of Kousseri in the north extreme province (sub-Saharan). Children from 2 months to 15 years of age attending these hospitals with fever (>38°C), clinical signs and symptoms of meningitis, and a lumbar puncture showing a turbid aspect with more than 50 polymorphonuclear cells/mm 3 were enrolled after informed written consent by a parent responsible for the child was obtained. The management and treatment of these children were not modified by the study and kept under the responsibility of the physician in charge of the patient.
Demographics, clinical data, length of hospital stay and outcome were recorded for all children. One milliliter of cerebrospinal fluid (CSF) was immediately stored at −20°C and transported every 6 months in dried ice to the Laboratory of Bacteriology at the University Hospitals of Geneva, Geneva, Switzerland, for bacterial DNA extraction and polymerase chain reaction (PCR) amplification targeting S.pneumoniae, Hib and N. meningitidis as previously described. 10 In case of a positive PCR result for S. pneumoniae, a second confirmation PCR was performed targeting the lytA gene.
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For N. meningitidis, DNA was then amplified with a real-time PCR to detect the ctrA gene 10 and, whenever this first PCR assay was positive, we performed a second amplification to detect the genes encoding the specific polysialyltransferase (siaD gene) for B, C, Y/ W135 serogroups and mynB gene for A serogroup, respectively. 12 Detection and identification of S. pneumoniae was done using a S. pneumoniae serotyping assay that genotypes 8 capsular genes to identify pneumococcal serotypes.
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Statistics
Categoric baseline data were expressed in percentages, and compared using Pearson χ 2 tests. Continuous baseline data were expressed using medians and interquartile ranges (IQRs), and compared with Kruskal-Wallis tests, with P considered significant under 0.05. Results were expressed in percentages for relative prevalence and case fatality by bacteria, age or socioeconomic group, and compared with odds ratios and 95% confidence intervals (CIs). The study was approved by the ethical committee of the Faculty of Medicine and Biomedical Sciences, Yaounde, Cameroon.
RESULTS
A total of 170 children were included in the study, and 71 (41.8%) were female. Eleven (6.5%) children suffered from moderate wasting (weight/height < −2 standard deviation), and 5 (2.9%) were severely malnourished (weight/height < −3 standard deviation). Sixteen (9.4%) were known to be HIV positive, and 8 were suffering from sickle cell disease, 2 with a homozygote form. All-cause mortality in meningitis cases was very high at 21.8%, and highly depended on age (logistic regression P = 0.03): we found a case fatality of 25.4% at age < 2 years, 30.8% between 2 and 5 years and it decreased to 5.3% at age > 5 years. We observed a bimodal distribution curve with a first mortality peak at age < 1 year (27.6%) and a second peak at 4 to 5 years of age (57.1%) due to the 3 types of bacteria: Hib and S.pneumoniae prevailed at 9 and 15 months, whereas meningococcal meningitis occurred around 72 months of age. Therefore, the odds ratio comparing mortality before and after 5 years was highly significant at 6.5 (95% CI: 1.5-28.4).
Overall, 24.7% of children with meningitis did not complete their treatment because of the lack of financial resources to pay a full antibiotic course. Case-fatality rate was the highest among pneumococcal meningitis (26.6%), followed by Hib (25.8%) and meningococcal meningitis (5.9%; Table 2 ). A significant, excess mortality was noted in children who could not afford the full antibiotic treatment: 43.9% versus 14.7%, odds ratio = 4.53 (95% CI: 2.06-9.94; P < 0.0001).
The bacterial type distribution in CSF varied substantially among the 3 sites (Table 1) . S. pneumoniae was predominant in Yaounde, Hib in Dschang (both cities in the south-west), whereas N. meningitidis was the main pathogen in Kousseri. Whereas the city of Kousseri is located in the extreme north province, part of the meningitis belt, 10 of 13 meningococcal strains recovered from this center belonged to the serogroup Y or W135 and only 3 to the serogroup A. Nine of 10 cases of serogroup Y or W135 occurred within 6 weeks from April 1 to May 15, 2008.
Hib meningitis had the second highest case-fatality rate, and 58.0% of children presented partial and generalized convulsion at the time of presentation to the emergency room. Twenty-two percent of children developed a coma (Glasgow Coma Scale < 8).
Pneumococcal meningitis occurred in 48.4% children below the age of 1 year, in 75.0% below 5 years of age but none before 3 months of age. More than 20 different pneumococcal serotypes were found ( Finally, 1 case was due to Salmonella sp and 1 case due to group B streptococcus, and no bacteria was recovered in 56 children despite biological signs of bacterial meningitis in the CSF (leukorachia, low glucose) and a case-fatality rate of 18.9%, suggesting a bacterial rather than a viral origin.
DISCUSSION
Acute bacterial meningitis (ABM) is a terrifying disease with a high case-fatality rate especially in countries where rapid access to medical care is limited as in subSaharan Africa. Furthermore, being diagnosed quickly is not a guarantee of success because many poor families can neither pay for hospitalization nor for antibiotic treatment. In our study, performed in 3 different sites in Cameroon, 24% of children with acute meningitis did not receive a complete antibiotic course due to the lack of financial resources. The overall mortality was 21.8%, but increased to 43.9% in those who did not receive a full antibiotic course. Although vaccination cannot abolish social differences in Africa, it could reduce the inequality gap by giving most children access to mass vaccination campaigns as has been shown successfully for measles and polio. However, ABM is a more difficult issue because the causative agents are multiple, and costeffectiveness and impact studies have not determined which vaccine could have the maximum benefit in this population. In Cameroon, few data exist, and none concerning the incidence rates of ABM. Fonkoua et al 14 reported that in Yaounde, S. pneumoniae was responsible for 56.2%, Hib 18.5% and N. meningitidis 13.4% of all ABM, a distribution close to our report with 57.1%, 27.7% and 15.2% for S. pneumoniae, Hib and N. meningitidis, respectively, and also to ratios found in other African countries. 2, 15 Even in neighboring countries located in the African meningitis belt, Gessner et al 6 showed that S. pneumoniae was the leading pathogen, in the absence of epidemics of N. meningitidis, with a mean annual incidence rate of 98 and 7.8 to 14 per 100,000 among persons < 1 year of age and 1-19 years of age, respectively.
If more than 90% of ABM caused by H. influenzae are of serotype b, the situation is more complex with N. meningitidis where 5 different serogroups are involved and even more difficult with S.pneumoniae where more than 90 serotypes cause invasive diseases. In Africa, especially in the African meningitis belt, N. meningitidis of the serogroup A is predominant, 16 although several reports showed that the serogroup W 135 incidence rate is increasing, 17 especially in pilgrims going to Mecca for the hadj. In our study, 10 cases of ABM due to the serogroup Y or W 135 occurred in the same center in a period of 6 weeks, suggesting an epidemic. Unfortunately, in the study period, we had no molecular technique to differentiate between serogroup Y or serogroup W 135 , and no data were available about travel and pilgrimage in the relatives of these children. As reported in many other African countries, 2,18 our study showed that S. pneumoniae is the leading ABM pathogen in Cameroon, associated with a high case-fatality rate. Therefore, a special effort has to be made to increase the implementation of pneumococcal conjugate vaccines in this continent as recommended by the World Health Organization in 2007. However, pneumococcal serotype distribution varies from one country to the other, and serotype circulation must be determined to calculate the potential impact of an immunization program. In Burkina Faso (northwest Africa), serotypes 1, 6A, 5 and 2 were predominant in ABM before the introduction of pneumococcal conjugate vaccines, 2 in Uganda (central-east Africa) 6A, 6B, 22A and 23F, 19 whereas in Tunisia (north Africa), serotypes 19F, 19A, 14 and 23F were recovered most often. 20 In a recent publication reviewing studies of invasive pneumococcal diseases causing serotypes, Johnson et al 8 found data from 13 of 53 (24.5%) African countries and calculated a maximal coverage of 49% (95% CI: 41-57%) for 7-valent pneumococcal conjugate vaccine, 72% (95% CI: 67-76%) for 10-valent pneumococcal conjugate vaccine and 77% (95% CI: 71-82%) for PCV-13, in children below 5 years of age, allowing potentially the prevention of 3.7 million cases of pneumococcal diseases in this continent each year. However, if the PCV-13 coverage reached 79.07% in Kenya and Uganda and even 100% in Tanzania, 21 nonvaccine serotypes seem to be more prevalent in countries situated in western Africa. For instance, in Burkina Faso and Togo, the 7-valent, 10-valent and 13-valent PCVs would cover 6%, 39% and 67% of serotypes identified among children aged < 5 years, respectively, 2 rates similar to those we reported in Cameroon. In our study, serotypes 32A-32F, which cannot be differentiated in the assay we used, accounted for 12.1% of all serotypes, occurring in 5 of 7 cases in infants aged 5 months or less, and equally distributed between participating centers. This serotype is rarely reported as causing invasive diseases except in a study from Uganda where serotype 32A accounted for 3% of all cases of pneumococcal meningitis. 19 In conclusion, our study is the first to report pneumococcal serotypes causing meningitis in children in Cameroon, a Global Alliance for Vaccines and Immunization-eligible country that introduced PCV-13 in July 2011. Despite the relatively low number of patients in this study, the calculated maximal coverage of this vaccine (62%) was less than what was estimated for other African countries and this has to be taken into account in the expected impact on pneumococcal meningitis in this country.
